Day 2 Highlights From the 20th International Myeloma Society Annual Meeting
October 02, 2023
October 02, 2023
NORWALK, Connecticut, Oct. 2 (TNSres) -- The Multiple Myeloma Research Foundation issued the following news:
Day 2 of IMS brought us some recent findings covering a mix of different drug combinations for both newly diagnosed and relapsed/refractory myeloma. Let's dig into a big day of updates in myeloma treatment.
Pomalidomide, Velcade, Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Revlimid is a key drug in the treatment of newl . . .
Day 2 of IMS brought us some recent findings covering a mix of different drug combinations for both newly diagnosed and relapsed/refractory myeloma. Let's dig into a big day of updates in myeloma treatment.
Pomalidomide, Velcade, Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Revlimid is a key drug in the treatment of newl . . .